Sir Gregory Winter

Sir Gregory Winter. A pioneering British molecular biologist, he is celebrated for his revolutionary work in protein engineering and the development of therapeutic antibodies. His research, primarily conducted at the MRC Laboratory of Molecular Biology in Cambridge, harnessed the power of phage display to create humanised and fully human antibodies, transforming the treatment of diseases like cancer and autoimmune disorders. For these contributions, he was jointly awarded the Nobel Prize in Chemistry in 2018 alongside Frances Arnold and George Smith.

Early life and education

Born in Leicester, Winter was educated at the Royal Grammar School, High Wycombe. He proceeded to study Natural Sciences at Trinity College, Cambridge, where he developed a keen interest in biochemistry. He remained at the University of Cambridge for his doctoral research, earning a PhD in 1977 for work on the amino acid sequences of proteins under the supervision of Brian S. Hartley. His early academic environment at the MRC Laboratory of Molecular Biology, a hub for pioneering work in molecular biology, profoundly shaped his future research direction.

Career and research

Winter's entire scientific career has been centered at the MRC Laboratory of Molecular Biology and the University of Cambridge. In the 1980s, building on the phage display technology pioneered by George Smith, he conceived the groundbreaking idea of using it to engineer antibodies. This work led to the founding of Cambridge Antibody Technology, a company instrumental in translating his research into medicines. He later served as the Master of Trinity College, Cambridge from 2012 to 2019. His leadership has also extended to Bicycle Therapeutics, a biopharmaceutical company he co-founded, exploring new modalities in therapy.

Humanised and fully human antibodies

Winter's most transformative achievement was solving the critical problem of immunogenicity caused by rodent-derived antibodies in humans. His team first developed techniques to "humanise" these antibodies, grafting the critical rodent complementarity-determining regions onto a human antibody framework. This breakthrough was followed by the creation of the first fully human antibodies directly from phage display libraries, bypassing animal immunization entirely. These technologies enabled the development of blockbuster drugs such as adalimumab (marketed as Humira for rheumatoid arthritis), trastuzumab (Herceptin for breast cancer), and many others, revolutionizing biotechnology and medicine.

Awards and honours

Winter's contributions have been recognized with numerous prestigious awards. He was appointed a Knight Bachelor in 2004 for services to molecular biology. He is a Fellow of the Royal Society and received the Royal Medal in 2011. The pinnacle of his recognition came in 2018 when he was awarded the Nobel Prize in Chemistry, sharing the prize with Frances Arnold and George Smith. Other significant honours include the EMBO Gold Medal, the Gairdner Foundation International Award, and the Prince of Asturias Award for Technical and Scientific Research.

Personal life

Winter is known to maintain a relatively private personal life focused on his scientific pursuits. He has been married and has children. His commitment to applying scientific discovery to practical medicine is a defining characteristic, evidenced by his active role in founding and guiding several successful biotechnology companies. He continues to be an active researcher and influential figure in the global scientific community, based in Cambridge.

Category:British biochemists Category:Nobel laureates in Chemistry Category:Knights Bachelor Category:Fellows of the Royal Society Category:Alumni of the University of Cambridge Category:People from Leicester Category:1951 births Category:Living people